A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation.

Vanessa Redecke¹, Kazuki Tawaratsumida¹, Erin T Larragoite², Elizabeth S C P Williams², Vicente Planelles², Adam M Spivak³, Lincoln Hirayama⁴, Marc Elgort⁴, Shane Swenson⁵, Rick Smith⁵, Bryan Worthen⁵, Russ Zimmerman⁵, Patricia Slev⁴, Ben Cahoon⁵, Mark Astill⁴, Hans Häcker⁶

¹Laboratory of Innate Immunity and Signal Transduction, Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.

²Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.

³Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

⁴Associated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, UT, USA.

⁵Techcyte Inc., Lindon, UT, USA.

⁶Laboratory of Innate Immunity and Signal Transduction, Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. hans.haecker@path.utah.edu.

PubMed PMC DOI PDF

Abstract

Diagnostic tests that detect antibodies (AB) against SARS-CoV-2 for evaluation of seroprevalence and guidance of health care measures are important tools for managing the COVID-19 pandemic. Current tests have certain limitations with regard to turnaround time, costs and availability, particularly in point-of-care (POC) settings. We established a hemagglutination-based AB test that is based on bi-s…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.